Executives from Airbus, AstraZeneca and HSBC are joining Prime Minister Keir Starmer on a rare China visit, highlighting the ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open. | AstraZeneca is showing no signs of ...

Citi launched broad coverage of major European pharmaceutical companies with a mixed outlook, issuing Buy ratings on AstraZeneca and Novartis while taking a more cautious stance on GSK, Novo Nordisk ...

Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue target AstraZeneca set for 2030 is already "very much within reach," Chief ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

AstraZeneca could build a new six-storey block at Cambridge Biomedical Campus (CBC) to house offices and a conference centre.

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...

Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, expanding the companies' existing collaboration to advance the application ...

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.